New stock news | Meigia Technology's Hong Kong IPO prospectus has expired.
MagniTech's Hong Kong IPO prospectus has expired.
The Hong Kong IPO prospectus submitted by Magia Technology Limited (hereinafter referred to as Magia Technology) on June 25 will expire after 6 months on December 25, with Morgan Stanley, Huatai International, Deutsche Bank, and China International Capital Corporation acting as joint sponsors at the time of submission.
According to the prospectus, Magia Technology is a leading provider of autonomous intelligent robots in the field of technology applications for Siasun Robot & Automation in China, dedicated to improving productivity for enterprises in smart laboratories and intelligent manufacturing scenarios and driving innovation.
Leveraging proprietary technology in automation and AI perception, conception, and execution in the field of Siasun Robot & Automation technology, Magia Technology's multi-functional autonomous intelligent robots excel in independently completing complex tasks, freeing up human resources to focus on high-value tasks in laboratory and manufacturing settings. This helps enterprises embrace intelligent transformation and make forward-looking layouts for the development of fields such as the next generation of research and manufacturing.
Related Articles

New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?

"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).

The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).
New stock outlook | Accounts receivable accounts for more than 60% of revenue, how can Youlesai tell a good story of circular packaging?

"Zootopia 2" breaks box office records and tops the animated film box office champion of Walt Disney Company(DIS.US).

The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).






